A phase i study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen

Kazuhiro Kakimi, Midori Isobe, Akiko Uenaka, Hisashi Wada, Eiichi Sato, Yuichiro Doki, Jun Nakajima, Yasuyuki Seto, Tomoki Yamatsuji, Yoshio Naomoto, Kenshiro Shiraishi, Nagio Takigawa, Katsuyuki Kiura, Kazuhide Tsuji, Keiji Iwatsuki, Mikio Oka, Linda Pan, Eric W. Hoffman, Lloyd J. Old, Eiichi Nakayama

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

We conducted a phase I clinical trial of a cancer vaccine using a 20-mer NY-ESO-1f peptide (NY-ESO-1 91-110) that includes multiple epitopes recognized by antibodies, and CD4 and CD8 T cells. Ten patients were immunized with 600 μg of NY-ESO-1f peptide mixed with 0.2 KE Picibanil OK-432 and 1.25 ml Montanide ISA-51. Primary end points of the study were safety and immune response. Subcutaneous injection of the NY-ESO-1f peptide vaccine was well tolerated. Vaccine-related adverse events observed were fever (Grade 1), injection-site reaction (Grade 1 or 2) and induration (Grade 2). Vaccination with the NY-ESO-1f peptide resulted in an increase or induction of NY-ESO-1 antibody responses in nine of ten patients. The sera reacted with recombinant NY-ESO-1 whole protein as well as the NY-ESO-1f peptide. An increase in CD4 and CD8 T cell responses was observed in nine of ten patients. Vaccine-induced CD4 and CD8 T cells responded to NY-ESO-1 91-108 in all patients with various HLA types with a less frequent response to neighboring peptides. The findings indicate that the 20-mer NY-ESO-1f peptide includes multiple epitopes recognized by CD4 and CD8 T cells with distinct specificity. Of ten patients, two with lung cancer and one with esophageal cancer showed stable disease. Our study shows that the NY-ESO-1f peptide vaccine was well tolerated and elicited humoral, CD4 and CD8 T cell responses in immunized patients.

Original languageEnglish
Pages (from-to)2836-2846
Number of pages11
JournalInternational Journal of Cancer
Volume129
Issue number12
DOIs
Publication statusPublished - Dec 15 2011

Fingerprint

Picibanil
Vaccination
Antigens
Peptides
T-Lymphocytes
Neoplasms
Subunit Vaccines
Epitopes
Vaccines
Clinical Trials, Phase I
Cancer Vaccines
Subcutaneous Injections
Esophageal Neoplasms
Antibody Formation
montanide ISA 51
Lung Neoplasms
Fever
Safety
Injections
Antibodies

Keywords

  • cancer vaccine
  • immune response
  • long peptide
  • NY-ESO-1

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

A phase i study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. / Kakimi, Kazuhiro; Isobe, Midori; Uenaka, Akiko; Wada, Hisashi; Sato, Eiichi; Doki, Yuichiro; Nakajima, Jun; Seto, Yasuyuki; Yamatsuji, Tomoki; Naomoto, Yoshio; Shiraishi, Kenshiro; Takigawa, Nagio; Kiura, Katsuyuki; Tsuji, Kazuhide; Iwatsuki, Keiji; Oka, Mikio; Pan, Linda; Hoffman, Eric W.; Old, Lloyd J.; Nakayama, Eiichi.

In: International Journal of Cancer, Vol. 129, No. 12, 15.12.2011, p. 2836-2846.

Research output: Contribution to journalArticle

Kakimi, K, Isobe, M, Uenaka, A, Wada, H, Sato, E, Doki, Y, Nakajima, J, Seto, Y, Yamatsuji, T, Naomoto, Y, Shiraishi, K, Takigawa, N, Kiura, K, Tsuji, K, Iwatsuki, K, Oka, M, Pan, L, Hoffman, EW, Old, LJ & Nakayama, E 2011, 'A phase i study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen', International Journal of Cancer, vol. 129, no. 12, pp. 2836-2846. https://doi.org/10.1002/ijc.25955
Kakimi, Kazuhiro ; Isobe, Midori ; Uenaka, Akiko ; Wada, Hisashi ; Sato, Eiichi ; Doki, Yuichiro ; Nakajima, Jun ; Seto, Yasuyuki ; Yamatsuji, Tomoki ; Naomoto, Yoshio ; Shiraishi, Kenshiro ; Takigawa, Nagio ; Kiura, Katsuyuki ; Tsuji, Kazuhide ; Iwatsuki, Keiji ; Oka, Mikio ; Pan, Linda ; Hoffman, Eric W. ; Old, Lloyd J. ; Nakayama, Eiichi. / A phase i study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. In: International Journal of Cancer. 2011 ; Vol. 129, No. 12. pp. 2836-2846.
@article{0e6b9f9de92642798250a5f106fffc5e,
title = "A phase i study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen",
abstract = "We conducted a phase I clinical trial of a cancer vaccine using a 20-mer NY-ESO-1f peptide (NY-ESO-1 91-110) that includes multiple epitopes recognized by antibodies, and CD4 and CD8 T cells. Ten patients were immunized with 600 μg of NY-ESO-1f peptide mixed with 0.2 KE Picibanil OK-432 and 1.25 ml Montanide ISA-51. Primary end points of the study were safety and immune response. Subcutaneous injection of the NY-ESO-1f peptide vaccine was well tolerated. Vaccine-related adverse events observed were fever (Grade 1), injection-site reaction (Grade 1 or 2) and induration (Grade 2). Vaccination with the NY-ESO-1f peptide resulted in an increase or induction of NY-ESO-1 antibody responses in nine of ten patients. The sera reacted with recombinant NY-ESO-1 whole protein as well as the NY-ESO-1f peptide. An increase in CD4 and CD8 T cell responses was observed in nine of ten patients. Vaccine-induced CD4 and CD8 T cells responded to NY-ESO-1 91-108 in all patients with various HLA types with a less frequent response to neighboring peptides. The findings indicate that the 20-mer NY-ESO-1f peptide includes multiple epitopes recognized by CD4 and CD8 T cells with distinct specificity. Of ten patients, two with lung cancer and one with esophageal cancer showed stable disease. Our study shows that the NY-ESO-1f peptide vaccine was well tolerated and elicited humoral, CD4 and CD8 T cell responses in immunized patients.",
keywords = "cancer vaccine, immune response, long peptide, NY-ESO-1",
author = "Kazuhiro Kakimi and Midori Isobe and Akiko Uenaka and Hisashi Wada and Eiichi Sato and Yuichiro Doki and Jun Nakajima and Yasuyuki Seto and Tomoki Yamatsuji and Yoshio Naomoto and Kenshiro Shiraishi and Nagio Takigawa and Katsuyuki Kiura and Kazuhide Tsuji and Keiji Iwatsuki and Mikio Oka and Linda Pan and Hoffman, {Eric W.} and Old, {Lloyd J.} and Eiichi Nakayama",
year = "2011",
month = "12",
day = "15",
doi = "10.1002/ijc.25955",
language = "English",
volume = "129",
pages = "2836--2846",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "12",

}

TY - JOUR

T1 - A phase i study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen

AU - Kakimi, Kazuhiro

AU - Isobe, Midori

AU - Uenaka, Akiko

AU - Wada, Hisashi

AU - Sato, Eiichi

AU - Doki, Yuichiro

AU - Nakajima, Jun

AU - Seto, Yasuyuki

AU - Yamatsuji, Tomoki

AU - Naomoto, Yoshio

AU - Shiraishi, Kenshiro

AU - Takigawa, Nagio

AU - Kiura, Katsuyuki

AU - Tsuji, Kazuhide

AU - Iwatsuki, Keiji

AU - Oka, Mikio

AU - Pan, Linda

AU - Hoffman, Eric W.

AU - Old, Lloyd J.

AU - Nakayama, Eiichi

PY - 2011/12/15

Y1 - 2011/12/15

N2 - We conducted a phase I clinical trial of a cancer vaccine using a 20-mer NY-ESO-1f peptide (NY-ESO-1 91-110) that includes multiple epitopes recognized by antibodies, and CD4 and CD8 T cells. Ten patients were immunized with 600 μg of NY-ESO-1f peptide mixed with 0.2 KE Picibanil OK-432 and 1.25 ml Montanide ISA-51. Primary end points of the study were safety and immune response. Subcutaneous injection of the NY-ESO-1f peptide vaccine was well tolerated. Vaccine-related adverse events observed were fever (Grade 1), injection-site reaction (Grade 1 or 2) and induration (Grade 2). Vaccination with the NY-ESO-1f peptide resulted in an increase or induction of NY-ESO-1 antibody responses in nine of ten patients. The sera reacted with recombinant NY-ESO-1 whole protein as well as the NY-ESO-1f peptide. An increase in CD4 and CD8 T cell responses was observed in nine of ten patients. Vaccine-induced CD4 and CD8 T cells responded to NY-ESO-1 91-108 in all patients with various HLA types with a less frequent response to neighboring peptides. The findings indicate that the 20-mer NY-ESO-1f peptide includes multiple epitopes recognized by CD4 and CD8 T cells with distinct specificity. Of ten patients, two with lung cancer and one with esophageal cancer showed stable disease. Our study shows that the NY-ESO-1f peptide vaccine was well tolerated and elicited humoral, CD4 and CD8 T cell responses in immunized patients.

AB - We conducted a phase I clinical trial of a cancer vaccine using a 20-mer NY-ESO-1f peptide (NY-ESO-1 91-110) that includes multiple epitopes recognized by antibodies, and CD4 and CD8 T cells. Ten patients were immunized with 600 μg of NY-ESO-1f peptide mixed with 0.2 KE Picibanil OK-432 and 1.25 ml Montanide ISA-51. Primary end points of the study were safety and immune response. Subcutaneous injection of the NY-ESO-1f peptide vaccine was well tolerated. Vaccine-related adverse events observed were fever (Grade 1), injection-site reaction (Grade 1 or 2) and induration (Grade 2). Vaccination with the NY-ESO-1f peptide resulted in an increase or induction of NY-ESO-1 antibody responses in nine of ten patients. The sera reacted with recombinant NY-ESO-1 whole protein as well as the NY-ESO-1f peptide. An increase in CD4 and CD8 T cell responses was observed in nine of ten patients. Vaccine-induced CD4 and CD8 T cells responded to NY-ESO-1 91-108 in all patients with various HLA types with a less frequent response to neighboring peptides. The findings indicate that the 20-mer NY-ESO-1f peptide includes multiple epitopes recognized by CD4 and CD8 T cells with distinct specificity. Of ten patients, two with lung cancer and one with esophageal cancer showed stable disease. Our study shows that the NY-ESO-1f peptide vaccine was well tolerated and elicited humoral, CD4 and CD8 T cell responses in immunized patients.

KW - cancer vaccine

KW - immune response

KW - long peptide

KW - NY-ESO-1

UR - http://www.scopus.com/inward/record.url?scp=84855170210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855170210&partnerID=8YFLogxK

U2 - 10.1002/ijc.25955

DO - 10.1002/ijc.25955

M3 - Article

C2 - 21448901

AN - SCOPUS:84855170210

VL - 129

SP - 2836

EP - 2846

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 12

ER -